Loading…
Filana Therapeutics Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.3% over 5Y.
today you would have $12.05▼ -98.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.98 | $2.36 | $22.51 | $29.54 | $43.70 | $6.82 | $5.20 | $0.85 | $4.00 | $3.99 | $12.25 | $14.21 | $34.02 | $18.97 | $26.60 | $47.25 | $37.52 | |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TVGNTevogen Inc. | $6.89 | — | — | — | — | $44.86M |
| MGXMetagenomi Therapeutics, Inc. | $1.19 | — | 0.4x | — | -60.61% | $44.95M |
| GRCEGrace Therapeutics, Inc. | $2.12 | — | 0.7x | — | -36.19% | $44.6M |
| MLSSMilestone Scientific Inc | $0.50 |
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Company description provided by Yahoo Finance.
| P/E |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 6.9x |
| — |
| — |
| — |
| — |
| P/S | 13.0x | — | — | — | — | — | — | — | — | — | — | — | — | 5.4x | 11.3x | 14.8x | 17.2x | — |
| P/B | 3.4x | 1.3x | 0.8x | 7.1x | 5.4x | 6.9x | 3.0x | 5.8x | 0.7x | 2.7x | 1.4x | 2.7x | 2.3x | 4.6x | 9.4x | 3.8x | 8.8x | — |
| EPS | -$1.88 | -$1.46 | -$2.32 | -$1.90 | -$0.82 | -$0.24 | -$0.27 | -$0.61 | -$1.82 | -$2.28 | -$2.17 | -$1.89 | $4.90 | -$0.56 | -$0.42 | -$1.96 | -$0.56 |
| Dividend yield | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 27.68% | — | 29.63% | — |
| Profit margin | -22.75% | — | — | — | — | — | — | — | — | — | — | — | — | 76.71% | -31.64% | -22.75% | -71.53% | -16.86% |
| ROE | -30.92% | -122.27% | -16.71% | -70.72% | -33.51% | -12.75% | -6.87% | -20.96% | -33.41% | -122.81% | -79.68% | -48.17% | -30.92% | 65.31% | -26.23% | -5.89% | -36.51% | -3.20% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 12.9x |
| — |
| -121.67% |
| $44.55M |
| EDSAEdesa Biotech, Inc. | $4.62 | — | 112.7x | — | -122.93% | $44.54M |
| QTIQt Imaging Holdings Inc | $3.09 | — | 19.0x | — | -2125.30% | $45.23M |